Hims & Hers Health, Inc. (NYSE:HIMS) Stake Cut by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. trimmed its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 18.3% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 214,500 shares of the company’s stock after selling 48,100 shares during the quarter. Hillsdale Investment Management Inc.’s holdings in Hims & Hers Health were worth $5,187,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of HIMS. Victory Capital Management Inc. boosted its holdings in shares of Hims & Hers Health by 164.9% during the third quarter. Victory Capital Management Inc. now owns 51,577 shares of the company’s stock valued at $950,000 after acquiring an additional 32,108 shares during the period. Quest Partners LLC boosted its holdings in shares of Hims & Hers Health by 22.6% during the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after acquiring an additional 807 shares during the period. Intech Investment Management LLC acquired a new position in shares of Hims & Hers Health during the third quarter valued at $1,064,000. Massachusetts Financial Services Co. MA acquired a new position in shares of Hims & Hers Health during the third quarter valued at $2,395,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Hims & Hers Health by 15.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock valued at $30,714,000 after acquiring an additional 218,566 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Trading Up 5.8 %

Shares of Hims & Hers Health stock opened at $34.77 on Friday. The company’s 50-day moving average price is $39.21 and its two-hundred day moving average price is $28.69. Hims & Hers Health, Inc. has a 52 week low of $11.20 and a 52 week high of $72.98. The stock has a market cap of $7.72 billion, a PE ratio of 79.02 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HIMS has been the subject of several analyst reports. Truist Financial boosted their price target on shares of Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a report on Wednesday, February 26th. Piper Sandler lifted their price objective on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, February 25th. Citigroup restated a “sell” rating and set a $27.00 price objective on shares of Hims & Hers Health in a research note on Thursday, March 6th. Bank of America lifted their price objective on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research note on Tuesday. Finally, Leerink Partners lifted their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research note on Tuesday, February 25th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and an average target price of $37.31.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Soleil Boughton sold 268,932 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the sale, the insider now owns 169,803 shares in the company, valued at approximately $4,712,033.25. The trade was a 61.30 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Michael Chi sold 17,303 shares of the business’s stock in a transaction dated Tuesday, December 24th. The stock was sold at an average price of $27.97, for a total value of $483,964.91. Following the sale, the insider now owns 193,601 shares in the company, valued at approximately $5,415,019.97. The trade was a 8.20 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,015,547 shares of company stock worth $36,146,450. Company insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.